Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya H Buch

Showing results (31-40 of 180) with videos related to

Pageof 18
Sort By:
Annals of the Rheumatic Diseases|March 8, 2011
Reporting of long-term extension studies: lack of consistency calls for consensusMaya H Buch, Daniel Aletaha, Paul Emery, et al.
Annals of the Rheumatic Diseases|November 30, 2016
The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to beGraham J Fent, John P Greenwood, Sven Plein, et al.
EULAR Rheumatology Open|June 29, 2026
Characterising subgroups of difficult-to-treat rheumatoid arthritis in real-world clinical settingsYvonne Tan, George Rogers, Rudresh Shukla, et al.
Arthritis Research & Therapy|October 26, 2017
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Vasco C Romão, Edward M Vital, João Eurico Fonseca, et al.
Drugs|May 4, 2020
Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic ApproachAndrew R Melville, Lianne Kearsley-Fleet, Maya H Buch, et al.
Journal of Scleroderma and Related Disorders|March 24, 2025
International expert agreement on World Scleroderma Foundation/Heart Failure Association consensus-based definition and guidance on screening, diagnosis, and follow-up assessment of systemic sclerosis-associated primary heart involvementVitalii Dubas, Maya H Buch, Petar Seferovic, et al.
Rheumatology (Oxford, England)|December 17, 2020
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathwayJohn Fitton, Andrew R Melville, Paul Emery, et al.
Annals of the Rheumatic Diseases|January 21, 2014
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trialEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Annals of the Rheumatic Diseases|March 18, 2014
Response to Dr Bredemeier's letterEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Rheumatology (Oxford, England)|October 17, 2016
Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?Giuseppina Abignano, Lesley-Anne Bissell, Paul Emery, et al.
Pageof 18

Showing results (31-40 of 180) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|March 8, 2011
Reporting of long-term extension studies: lack of consistency calls for consensusMaya H Buch, Daniel Aletaha, Paul Emery, et al.
Annals of the Rheumatic Diseases|November 30, 2016
The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to beGraham J Fent, John P Greenwood, Sven Plein, et al.
EULAR Rheumatology Open|June 29, 2026
Characterising subgroups of difficult-to-treat rheumatoid arthritis in real-world clinical settingsYvonne Tan, George Rogers, Rudresh Shukla, et al.
Arthritis Research & Therapy|October 26, 2017
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Vasco C Romão, Edward M Vital, João Eurico Fonseca, et al.
Drugs|May 4, 2020
Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic ApproachAndrew R Melville, Lianne Kearsley-Fleet, Maya H Buch, et al.
Journal of Scleroderma and Related Disorders|March 24, 2025
International expert agreement on World Scleroderma Foundation/Heart Failure Association consensus-based definition and guidance on screening, diagnosis, and follow-up assessment of systemic sclerosis-associated primary heart involvementVitalii Dubas, Maya H Buch, Petar Seferovic, et al.
Rheumatology (Oxford, England)|December 17, 2020
Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathwayJohn Fitton, Andrew R Melville, Paul Emery, et al.
Annals of the Rheumatic Diseases|January 21, 2014
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trialEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Annals of the Rheumatic Diseases|March 18, 2014
Response to Dr Bredemeier's letterEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Rheumatology (Oxford, England)|October 17, 2016
Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?Giuseppina Abignano, Lesley-Anne Bissell, Paul Emery, et al.
Pageof 18